# A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

> **NCT05315830** · PHASE1 · UNKNOWN · sponsor: **The First Affiliated Hospital of Bengbu Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Adenocarcinoma - GEJ
- Adenocarcinoma of the Stomach

## Interventions

- **BIOLOGICAL:** HER2 Tumor Vaccine
- **BIOLOGICAL:** HER2 Tumor Vaccine+ Standard of Care chemotherapy

## Key facts

- **NCT ID:** NCT05315830
- **Lead sponsor:** The First Affiliated Hospital of Bengbu Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-07
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05315830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05315830, "A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05315830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*